Sustained imaging response and hearing preservation with low-dose bevacizumab in sporadic vestibular schwannoma. uri icon

Overview

publication date

  • June 10, 2019

Research

keywords

  • Antineoplastic Agents, Immunological
  • Bevacizumab
  • Hearing Loss
  • Magnetic Resonance Imaging
  • Neuroma, Acoustic

Identity

PubMed Central ID

  • PMC4724182

Scopus Document Identifier

  • 85067538700

Digital Object Identifier (DOI)

  • 10.1093/neuonc/noz051

PubMed ID

  • 31180122

Additional Document Info

volume

  • 21

issue

  • 6